Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan.
Anticancer Res. 2013 May;33(5):2211-9.
BACKGROUND/AIM: We aimed to examine the relationship between antibodies to hepatitis B core antigen (anti-HBc) positivity and survival in patients with non-B non-C hepatocellular carcinoma (NBNC-HCC) who underwent curative treatment.
A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 124 anti-HBc-positive patients (47.7%) and 136 anti-HBc-negative patients (52.3%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared.
The 3-year cumulative OS rates were 75.9% in the anti-HBc-positive group and 82.3% in the anti-HBc-negative group (p=0.069). The corresponding RFS rates were 29.8% in the anti-HBc-positive group and 43.0% in the anti-HBc-negative group (p=0.001). Multivariate analyses identified anti-HBc positivity (p=0.006), aspartate aminotransferase ≥ 40 IU/l (p=0.037) and des-γ-carboxy prothrombin ≥ 100 mAU/ml (p=0.046) as significant adverse predictors were linked to RFS.
Anti-HBc positivity can be a useful predictor for recurrence in patients with NBNC-HCC after curative therapy.
背景/目的：我们旨在研究接受根治性治疗的非乙型肝炎非丙型肝炎肝细胞癌（NBNC-HCC）患者中，乙型肝炎核心抗原抗体（抗-HBc）阳性与生存之间的关系。
共分析了 260 例接受根治性治疗的 NBNC-HCC 患者。他们包括 124 例抗-HBc 阳性患者（47.7%）和 136 例抗-HBc 阴性患者（52.3%）。比较了总生存（OS）和无复发生存（RFS）率。
抗-HBc 阳性组的 3 年累积 OS 率为 75.9%，抗-HBc 阴性组为 82.3%（p=0.069）。相应的 RFS 率在抗-HBc 阳性组为 29.8%，在抗-HBc 阴性组为 43.0%（p=0.001）。多因素分析确定抗-HBc 阳性（p=0.006）、天门冬氨酸氨基转移酶≥40IU/l（p=0.037）和去γ-羧基凝血酶原≥100mAU/ml（p=0.046）是与 RFS 相关的显著不良预测因素。
抗-HBc 阳性可作为根治性治疗后 NBNC-HCC 患者复发的有用预测指标。
